Phase 3 Recruiting Network
This trial has two cohorts of patients with human epidermal growth factor receptor (HER)-2-positive breast cancer that has spread to other places in the body. All patients must be receiving trastuzumab-based treatment. Both cohorts are bei…
Sponsor: SWOG Cancer Research Network
NCT ID: NCT03418961
Sites in Wisconsin: - Duluth Clinic Ashland — Ashland, Wisconsin
- Bellin Memorial Hospital — Green Bay, Wisconsin
- Mercyhealth Hospital and Cancer Center - Janesville — Janesville, Wisconsin
- Cancer Center of Western Wisconsin — New Richmond, Wisconsin
Phase 3 Recruiting Network
This phase III trial tests two hypotheses in patients with low-risk and average-risk medulloblastoma. Medulloblastoma is a type of cancer that occurs in the back of the brain. The term, risk, refers to the chance of the cancer coming back …
Sponsor: Children's Oncology Group
NCT ID: NCT05382338
Sites in Wisconsin: - University of Wisconsin Carbone Cancer Center - University Hospital — Madison, Wisconsin
- Marshfield Medical Center-Marshfield — Marshfield, Wisconsin
- Children's Hospital of Wisconsin — Milwaukee, Wisconsin
Phase 3 Recruiting Network
Stereotactic radiosurgery (SRS) is a commonly used treatment for brain tumors. It is a one-day (or in some cases two day), out-patient procedure during which a high dose of radiation is delivered to small spots in the brain while excluding…
Sponsor: Canadian Cancer Trials Group
NCT ID: NCT03550391
Sites in Wisconsin: - Medical College of Wisconsin — Milwaukee, Wisconsin
Phase 3 Recruiting Academic/Other
This phase III trial compares temporally-modulated pulsed radiation therapy versus standard radiation therapy in treating patients with newly diagnosed, IDH wildtype, MGMT-unmethylated glioblastoma. After completion of surgery, the standar…
Sponsor: NRG Oncology
NCT ID: NCT07452458
Sites in Wisconsin: - ThedaCare Regional Cancer Center — Appleton, Wisconsin
- University of Wisconsin Carbone Cancer Center - Johnson Creek — Johnson Creek, Wisconsin
- University of Wisconsin Carbone Cancer Center - Eastpark Medical Center — Madison, Wisconsin
- University of Wisconsin Carbone Cancer Center - University Hospital — Madison, Wisconsin
- Froedtert Menomonee Falls Hospital — Menomonee Falls, Wisconsin
Phase 3 Recruiting Industry
This is a 3-part study. The purpose of Part 1 of the study is to evaluate the efficacy, safety, and pharmacokinetic (PK) characteristics of safusidenib in participants with recurrent/progressive IDH1-mutant World Health Organization (WHO) …
Sponsor: Nuvation Bio Inc.
NCT ID: NCT05303519
Sites in Wisconsin: - University of Wisconsin Health — Madison, Wisconsin
Phase 2, Phase 3 Recruiting Academic/Other
Glioblastoma (GBM) adaptive, global, innovative learning environment (GBM AGILE) is an international, seamless Phase II/III response adaptive randomization platform trial designed to evaluate multiple therapies in newly diagnosed (ND) and …
Sponsor: Global Coalition for Adaptive Research
NCT ID: NCT03970447
Sites in Wisconsin: - Froedtert Hospital/Medical College of Wisconsin — Milwaukee, Wisconsin
Phase 2 Recruiting Network
This phase II trial compares the effect of encorafenib, binimetinib, and nivolumab versus ipilimumab and nivolumab in treating patients with BRAF- V600 mutant melanoma that has spread to the brain (brain metastases). Encorafenib and binime…
Sponsor: SWOG Cancer Research Network
NCT ID: NCT04511013
Sites in Wisconsin: - Langlade Hospital and Cancer Center — Antigo, Wisconsin
- Marshfield Medical Center-EC Cancer Center — Eau Claire, Wisconsin
- Gundersen Lutheran Medical Center — La Crosse, Wisconsin
- University of Wisconsin Carbone Cancer Center — Madison, Wisconsin
- Marshfield Medical Center-Marshfield — Marshfield, Wisconsin
Phase 2 Recruiting Network
This phase II trial studies the best approach to combine chemotherapy and radiation therapy (RT) based on the patient's response to induction chemotherapy in patients with non-germinomatous germ cell tumors (NGGCT) that have not spread to …
Sponsor: Children's Oncology Group
NCT ID: NCT04684368
Sites in Wisconsin: - University of Wisconsin Carbone Cancer Center - Eastpark Medical Center — Madison, Wisconsin
- University of Wisconsin Carbone Cancer Center - University Hospital — Madison, Wisconsin
- Marshfield Medical Center-Marshfield — Marshfield, Wisconsin
Phase 1, Phase 2 Recruiting NIH
This phase I/II trial tests the safety, side effects, and best dose of selinexor given in combination with standard radiation therapy in treating children and young adults with newly diagnosed diffuse intrinsic pontine glioma (DIPG) or hig…
Sponsor: National Cancer Institute (NCI)
NCT ID: NCT05099003
Sites in Wisconsin: - University of Wisconsin Carbone Cancer Center - University Hospital — Madison, Wisconsin
- Children's Hospital of Wisconsin — Milwaukee, Wisconsin
Phase 1, Phase 2 Recruiting NIH
This phase I/II trial tests the safety, side effects and best dose of selinexor given in combination with the usual chemotherapy (temozolomide) and compares the effect of this combination therapy versus the usual chemotherapy alone (temozo…
Sponsor: National Cancer Institute (NCI)
NCT ID: NCT05432804
Sites in Wisconsin: - University of Wisconsin Carbone Cancer Center - Eastpark Medical Center — Madison, Wisconsin
- University of Wisconsin Carbone Cancer Center - University Hospital — Madison, Wisconsin
Phase 2 Recruiting Industry
The objective of the study is to evaluate efficacy and safety of zanzalintinib in participants with recurrent or progressive meningioma refractory to standard therapies.
Sponsor: Exelixis
NCT ID: NCT07428616
Sites in Wisconsin: - UW Carbone Cancer Center — Madison, Wisconsin
Phase 2 Recruiting Industry
This is an open-label, multicenter Phase 2 study evaluating BMS-986504 in participants with advanced and/or metastatic solid tumors that have MTAP deletion. The study includes a monotherapy component and a combination component in which BM…
Sponsor: Bristol-Myers Squibb
NCT ID: NCT07492680
Sites in Wisconsin: - Local Institution - 0134 — Madison, Wisconsin
Phase 2 Recruiting Industry
To assess: * efficacy of APL-101 as monotherapy for the treatment of NSCLC harboring MET Exon 14 skipping mutations, NSCLC harboring MET amplification, solid tumors harboring MET amplification, solid tumors harboring MET fusion, primary CN…
Sponsor: Apollomics Inc.
NCT ID: NCT03175224
Sites in Wisconsin: - University of Wisconsin — Madison, Wisconsin
Phase 2 Recruiting Academic/Other
Study patients will receive Whole-brain radiation therapy (WBRT) - pulsed reduced dose rate (PRDR) within 14 days of registration. All patients will receive single daily fractions using 3D conformal radiotherapy. A dose of 30 Gy in 10 frac…
Sponsor: Medical College of Wisconsin
NCT ID: NCT05045950
Sites in Wisconsin: - Froedtert Hospital & the Medical College of Wisconsin — Milwaukee, Wisconsin
- Clement J. Zablocki Veterans Affairs Medical Center — Milwaukee, Wisconsin
Phase 1 Recruiting NIH
This phase I trial tests the safety, side effects, and best dose of triapine in combination with radiation therapy in treating patients with glioblastoma or astrocytoma that has come back after a period of improvement (recurrent). Triapine…
Sponsor: National Cancer Institute (NCI)
NCT ID: NCT06860594
Sites in Wisconsin: - University of Wisconsin Carbone Cancer Center - Eastpark Medical Center — Madison, Wisconsin
- University of Wisconsin Carbone Cancer Center - University Hospital — Madison, Wisconsin
NA Recruiting Industry
Randomized, post-market multi-center study investigating the efficacy of two sets of treatment algorithms in brain metastases (BM) patients at the time of first intervention for radiographic progression after stereotactic radiosurgery (SRS…
Sponsor: Monteris Medical
NCT ID: NCT05124912
Sites in Wisconsin: - Medical College of Wisconsin — Milwaukee, Wisconsin
Recruiting Academic/Other
The Multi-OutcoMe EvaluatioN of radiation Therapy Using the Unity MR-Linac Study (MOMENTUM) is a multi-institutional, international registry facilitating evidenced based implementation of the Unity MR-Linac technology and further technical…
Sponsor: UMC Utrecht
NCT ID: NCT04075305
Sites in Wisconsin: - Medical College of Wisconsin — Milwaukee, Wisconsin
Recruiting Academic/Other
This study aims to investigate a neurologic exam scale to provide an objective and more standard way to assess tumor response in pediatric patients with brain and spinal cord tumors.
Sponsor: University of Wisconsin, Madison
NCT ID: NCT06981156
Sites in Wisconsin: - American Family Children's Hospital — Madison, Wisconsin
NA Recruiting Academic/Other
The neurosurgical standard of care for treating a patient with a tumor invading hand primary motor cortex (M1) includes performing a craniotomy with intraoperative direct electrical stimulation (DES) mapping and to resect as much tumor as …
Sponsor: Medical College of Wisconsin
NCT ID: NCT05023434
Sites in Wisconsin: - Medical College of Wisconsin — Milwaukee, Wisconsin